Mirtor (Mirtazapine)

Mirtazapine, the active ingredient in Mirtor, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is indicated for the management of major depressive disorder in adult patients, helping to improve mood and functional outcomes.

GNH USA supplies Mirtor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing, comprehensive regulatory support and on‑time delivery.

Mirtor (mirtazapine) is used primarily in the treatment of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients. - Depressive symptoms with comorbid anxiety: helps alleviate both mood and anxiety components. - Insomnia associated with depression: its antihistaminic action can improve sleep continuity.

Mirtor may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypotension or syncope - Suicidal thoughts or behavior - Serotonin syndrome when combined with other serotonergic agents - Cardiac arrhythmias (e.g., QT prolongation)

Before initiating therapy with Mirtor, clinicians should consider several safety measures.

- Assess depression severity: evaluate baseline symptoms and suicide risk. - Monitor for suicidal ideation: especially during early treatment and dose changes. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal effects. - Elderly patients: watch for increased sedation and falls. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Mirtor can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension or serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): may precipitate serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors or inducers (e.g., ketoconazole, rifampicin): may alter mirtazapine plasma levels. - Antihypertensive drugs: additive hypotensive effect. - Anticholinergic medications: may increase dry mouth and constipation.